46 results on '"Hudson, Chad"'
Search Results
2. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921
3. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia:Results From the Phase I Part of Study ITCC054/COG AAML1921
4. CD74 is expressed in a subset of pediatric acute myeloid leukemia patients and is a promising target for therapy: a report from the Children’s Oncology Group
5. Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML
6. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
7. Emerging utility of flow cytometry in the diagnosis of chronic myelomonocytic leukemia
8. P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA
9. The impact of Down syndrome‐specific non‐malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual disease
10. Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABL and CBFA2T3::GLIS2 Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor
11. A Novel Multi-Analytic Clinical Diagnostic Assay to Detect HLA Loss of Heterozygosity in Post-Hematopoietic Cell Transplant Relapse Patients
12. CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol
13. Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease
14. The control of reactive oxygen species production by SHP-1 in oligodendrocytes
15. Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype
16. Residual Mast Cells Can Explain Persistent Molecular Positivity in Difference from Normal Flow Cytometric-Defined MRD Negative Core Binding Factor AML
17. SHP-1 deficiency and increased inflammatory gene expression in PBMCs of multiple sclerosis patients
18. Chronic foot shock induces hyperactive behaviors and accompanying pro- and anti-inflammatory responses in mice
19. Antibody induction of lupus-like neuropsychiatric manifestations
20. Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol
21. Evaluation of the procoagulant properties of a newly developed platelet modified lysate product
22. 90 Modulation of macrophage infiltration and inflammatory activity by the phosphatase SHP-1 in virus-induced demyelinating disease
23. Promoter-specific induction of the phosphatase SHP-1 by viral infection and cytokines in CNS glia
24. Inverse regulation of inducible nitric oxide synthase (iNOS) and arginase I by the protein tyrosine phosphatase SHP-1 in CNS glia
25. Immune Changes during Acute Cold/Restraint Stress-Induced Inhibition of Host Resistance to Listeria
26. Steroid hormones modulate expression of cytochrome P450 enzymes in male hamster reproductive tract and leiomyosarcomas
27. Acute cold/restraint stress inhibits host resistance to Listeria monocytogenes via β1-adrenergic receptors
28. Concurrent Polycythemia of Undetermined Etiology and Smouldering Plasma Cell Myeloma
29. Clinical Utility of Classical and Nonclassical Monocyte Percentage in the Diagnosis of Chronic Myelomonocytic Leukemia
30. Expected Dangerously Low Potassium Concentrations
31. Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).
32. Pediatric Acute Myeloid Leukemia with Co-Occurring BCR::ABLand CBFA2T3::GLIS2Dual Fusion with Deep Response to FOLR1-Targeting Antibody Drug Conjugate Stro-002 and Tyrosine Kinase Inhibitor
33. Interferon-β treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1
34. Modulation of Macrophage Infiltration and Inflammatory Activity by the Phosphatase SHP-1 in Virus-Induced Demyelinating Disease
35. Induction of IL-33 expression and activity in central nervous system glia
36. Direct Induction of Arginase I and Cytokines by IL‐33 in CNS Glia
37. Erratum to “Antibody induction of lupus-like neuropsychiatric manifestations”[J. Neuroimmunol. 182 (2007) 185–194]
38. Regulation of avoidant behaviors and pain by the anti-inflammatory tyrosine phosphatase SHP-1
39. Susceptibility of Lupus-Prone Nzm Mouse Strains to Lead Exacerbation of Systemic Lupus Erythematosus Symptoms
40. Exogenous 17β-Estradiol Blocks Alpha and Mu but Not Pi Class Glutathione S-Transferase Immunoreactivity in Epithelium of Syrian Hamster Vas Deferens
41. Glutathione S-transferase in hormonal carcinogenesis
42. Regulation of avoidant behaviors and pain by the anti-inflammatory tyrosine phosphatase SHP-1.
43. letters.
44. Measuring response to therapy in AML: Difference from normal flow cytometry vs RQ-PCR.
45. Interferon-beta treatment in multiple sclerosis attenuates inflammatory gene expression through inducible activity of the phosphatase SHP-1.
46. Erratum to "Antibody induction of lupus-like neuropsychiatric manifestations" [J.Neuroimmunol.182(2007) 185-194].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.